2. GOLD Executive Committee.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2015).www.goldcopd.com.
[3]
3. Cai BQ, Cai SX, Chen RC, et al.Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. IntJObstruet Pulmon Dis. 2014, 9: 381-395.
[4]
4. Criner GJ, Bourbeau J, Diekemper RL, et al.Prevention of Acute Exacerbations of COPD. American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest, 2015, 147:894-942.
[5]
5. Molyneaux PL, Mallia P, Cox MJ, et al.Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.AmJRespir Crit Care Med, 2013, 10:1224-1231.
[6]
6. Ye F, He LX, CAI BQ et al.Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China.Chin Med J, 2013, 126:2207-2214.
[7]
7. Hurst JR, Vestbo J, Anzueto A, et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease.N EnglJMed, 2010, 363:1128-1138.
[8]
8. Aaron SD.Management and prevention of exacerbations of COPD.BMJ, 2014, 349:g5237-5248.
[9]
9. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013, 309:2223-2231.
[10]
10. Bafadhel M, McKenna S, Terry S, et al.Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease.A randomized, placebo-controlled trial.AmJRespir Crit Care Med, 2012, 186:48-55.
[11]
11. Woodhead M, Blasi F, Ewig S, et al.Guidelines for the management of adult lower respiratory tract infections-full version.Clin Microbiol Infect, 2011, 17:E1-E59.
13. Mallia P, Singanayagam A, Johnston SL.Virus-bacteria interactions in COPD exacerbations.Eur Respir Monogr, 2013, 60: 76-83.
[14]
14. Aaron SD, Vandemheen KL, Maltais F, et al.TNF α antagonists for acute exacerbations of COPD:a randomised double blind controlled trial.Thorax, 2013, 68:142-148.
[15]
15. Kerwin E, Hebert J, Gallagher N, et al.Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD:the GLOW’ study.Eur Respir J, 2012, 40:1106-1114.
[16]
16. Wedzicha JA, Decramer M, Ficker JH, et al.Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium(SPARK):a randomised, double-blind, parallel-group study.Lancet Respir Med, 2013, 1:199-209.
[17]
18. Zheng JP, Wen FQ, Bai CX, et al.Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON):a randomised, double-blind placebo-controlled trial.Lancet Respir Med, 2014, 2:187-194.
[18]
17. Zhong NS, Wang CZ, Zhou XD, et al.LANTERN:a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.IntJChron Obstruct Pulmon Dis, 2015, 10:1015-1026.
[19]
19. Martinez FJ, Erb-Downward JR, Huffnagle GB. Significance of the microbiome in chronic obstructive pulmonary disease.Ann Am Thorac Soc, 2013, 10 Suppl:S170-S179.
[20]
20. Brightling CE.Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease.Ann Am Thorac Soc, 2013, 10 Suppl:S214-S219.
